Methods and treatments for the learning and memory deficits associated with Noonan syndrome
Disclosed herein are methods and compositions for treating learning and memory deficits associated with Noonan Syndrome.
1. A method of treating a cognitive deficit in a subject having Noonan syndrome, comprising:
administering an effective amount of one or more hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors to a subject having the cognitive deficit and Noonan syndrome.
2. The method of claim 1 , wherein the one or more HMG CoA inhibitors comprises a statin.
3. The method of claim 2 , wherein the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, pitavastatin, rovustatin, simvastatin, and mixtures thereof.
4. The method according to claim 1 , wherein the effective amount does not significantly lower total serum cholesterol level in the subject.
5. The method according to claim 1 , which further comprises administering a farnesyl transferase inhibitor, a geranylgeranyl transferase inhibitor, an inhibitor of γ-aminobutyric acid (GABA) mediated inhibition, an inhibitor of GABA receptor activity, and/or a modulator of Ras-ERK signaling.
6. The method according to claim 1 , wherein the supplementary compound is administered before, during, and/or after the inhibitor.
7. The method according to claim 1 , wherein the administering is by adjunctive administration.
8. The method of claim 7 , wherein the adjunctive administration is simultaneous administration.
9. The method of claim 7 , wherein the adjunctive administration is sequential administration.
10. The method of claim 1 , wherein said subject has a normal cholesterol level.
11. The method of claim 1 , which further comprises administering an effective amount of an inhibitor of MEK to the subject.
12. The method of claim 11 , wherein the inhibitor of MEK is a specific inhibitor of MEK1 and/or MEK2.
13. The method of claim 11 , wherein the inhibitor of MEK is α-(Amino((4-aminophenyl)thio)methylene)-2-(trifluoromethyl)benzeneacetonitrile (SL327).
14. The method of claim 11 , wherein the one or more hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors are administered before, during, and/or after administration of the inhibitor of MEK.
15. A method of improving cognitive function of a subject having a cognitive deficit and Noonan syndrome, comprising:
administering an effective amount of one or more hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors to a subject having the cognitive deficit and Noonan syndrome.